Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 15,039 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vascular Clear all

Conditions: Recurrent Multiple Myeloma
Interventions: Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Elotuzumab, Iberdomide, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Foot Ulcer
Interventions: Esmolol hydrochloride, Placebo gel; Drug
Lead sponsor: Novalead Pharma Private Limited; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Menkes Disease
Interventions: Droxidopa Oral Product, Placebo Control; Drug · Other
Lead sponsor: Stephen G. Kaler; Other
Eligibility: 7 Years to 17 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Venous Insufficiency
Interventions: cyrotherapy as a cool gel wrap; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 45 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Ruptured Aneurysm, Memory Deficits, Subarachnoid Hemorrhage
Interventions: Lumosity, Crossword puzzle; Device
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atrial Fibrillation
Interventions: Transesophageal Echocardiography; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Intracerebral Hemorrhage, ICH - Intracerebral Hemorrhage
Interventions: Minimally Invasive surgery (MIS), Deferoxamine, Standard Medical Care (SMD); Procedure · Drug · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sars-CoV2, COVID
Interventions: Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more

Conditions: Essential Hypertension
Interventions: Motivational Interviewing; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 1 Diabetes, Cardiovascular Diseases (CVD), Severe Albuminuria, Estimated Glomerular Filtration Rate (eGFR), Hypoglycemia (Diabetic), Vascular Calcification, Carotid-femoral Pulse Wave Velocity, Kidney Diseases
Interventions: Routine/prescribed exogenous insulin dose; Drug
Lead sponsor: Rachel Miller; Other
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Thoracoabdominal Aortic Aneurysm
Interventions: GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 19 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 34 more

Conditions: Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Burkitt Lymphoma, Adult Diffuse Large Cell Lymphoma, Adult Diffuse Mixed Cell Lymphoma, Adult Diffuse Small Cleaved Cell Lymphoma, Adult Hodgkin Lymphoma, Adult Immunoblastic Large Cell Lymphoma, Adult Lymphoblastic Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Breast Cancer, Chronic Eosinophilic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Cutaneous T-cell Non-Hodgkin Lymphoma, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3 Follicular Lymphoma, Malignant Testicular Germ Cell Tumor, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Multiple Myeloma, Mycosis Fungoides/Sezary Syndrome, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neutropenia, Nodal Marginal Zone B-cell Lymphoma, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Plasma Cell Neoplasm, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Primary Myelofibrosis, Prolymphocytic Leukemia, Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma
Interventions: cefepime hydrochloride; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Interventions: ATV-1601, Placebo; Drug
Lead sponsor: Atavistik Bio, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Phoenix, Arizona • San Diego, California • Augusta, Georgia + 6 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Thalidomide, zoledronic acid; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 4
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more

Conditions: Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions: Warfarin GenoSTAT Test; Device
Lead sponsor: Iverson Genetic Diagnostics, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 3,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 56
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more

Conditions: Hypertension, Cardiovascular Risk Factor, Physical Activity, Chronic Kidney Diseases
Interventions: FitBit; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 8 Years to 30 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Kaposi Sarcoma, HIV Infection
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Coronary Artery Disease
Interventions: The Multi-vessel Coronary Artery Disease Option Grid, Usual Care; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Portland, Maine • Lebanon, New Hampshire • Albany, New York

Conditions: Steno-occlusive Disease
Interventions: gadopiclenol, Gadoterate meglumine (Dotarem); Drug
Lead sponsor: Guerbet; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 3 more

Conditions: Pulmonary Embolism
Interventions: Anticoagulant Therapy, Catheter-Directed Therapy; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 40
States / cities: Birmingham, Alabama • Palo Alto, California • Sacramento, California + 33 more

Conditions: Cerebrovascular Accident, Hemiparesis
Interventions: Ropinirole (+ physical therapy), (vs.) Placebo + physical therapy; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Orange, California

Conditions: Obesity, Vitamin D Deficiency, Hypertension
Interventions: Vitamin D (cholecalciferol); Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pre-hypertension, Hypertension
Interventions: Potassium, Magnesium, Citrate, Potassium Chloride; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 95 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Chronic Stroke
Interventions: CO-OP Procedures, tDCS, Computer Cognitive Training Procedures, sham tDCS group; Behavioral · Device
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 85 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Columbia, Missouri

Search by objective public record fields.

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers

NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease

Feasibility Study of Cryotherapy for Chronic Venous Disorders

Memory Training in Aneurysmal Subarachnoid Hemorrhage Patients

Safety Monitoring of Patients Having Pulmonary Vein Ablation

Synergistic Minimally Invasive Surgery and Deferoxamine in ICH

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

Motivational Interviewing

Relationship Between Insulin Dose and Complications in Type 1 Diabetes

Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Activity Trackers for Improving BP

Development of Serologic Assays for Human Herpes Virus-8

Treatment Decisions for Multi-vessel CAD

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

Trial of Ropinirole in Motor Recovery After Stroke

Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity

Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients

tDCS and Metacognitive Strategy Training in Stroke